Clinical issues in use of atypical antipsychotics for depressed patients

CNS Drugs

Volumn 27, Issue SUPPL.1, 2013, Pages

  Pae, Chi Un ^a,b   Patkar, Ashwin A ^b  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

CLINICAL PRACTICE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; HUMAN; MAJOR DEPRESSION; PRIORITY JOURNAL; REVIEW; DRUG COMBINATION; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; TREATMENT OUTCOME;

EID: 84886301183     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-012-0032-z     Document Type: Review

References (60)

1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-105.
2. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR&z.ast;D) study. Psychiatr Clin North Am. 2003;26(2):457-94; x.
3. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR&z.ast;D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
4. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR&z.ast;D report. Am J Psychiatry. 2006;163(11):1905-17.
5. Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011;168(7): 689-701.
6. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000;157(4 Suppl.):1-45.
7. Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry. 2002;3(1):5-43.
8. Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22(4):343-96.
9. Kennedy SH, Lam RW, Cohen NL, Ravindran AV. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry; Revue canadienne de psychiatrie. 2001;46(Suppl. 1):38S-58S.
10. Philip NS, Carpenter LL, Tyrka AR, Price LH. Augmentation of antidepressants with atypical antipsychotics: a review of the current literature. J Psychiatr Pract. 2008;14(1):34-44.
11. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-91.
12. Sagud M, Mihaljevic-Peles A, Begic D, Vuksan-Cusa B, Kramaric M, Zivkovic M, et al. Antipsychotics as antidepressants: what is the mechanism? Psychiatr Danub. 2011;23(3):302-7.
13. Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs. 2011;25(2):109-27.
14. Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry. 2011;24(1):10-7.
15. Pae CU, Sohi MS, Seo HJ, Serretti A, Patkar AA, Steffens DC, et al. Quetiapine XR: current status for the treatment of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1165-73.
16. Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007;68(6):826-31.
17. Mischoulon D, Nierenberg AA, Kizilbash L, Rosenbaum JF, Fava M. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry; Revue Canadienne de Psychiatrie. 2000;45(5): 476-81.
18. Gaynes BN, Dusetzina SB, Ellis AR, Hansen RA, Farley JF, Miller WC, et al. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR&z.ast;D. J Clin Psychopharmacol. 2012;32(1):114-9.
19. Rush AJ, Warden D, Wisniewski SR, Fava M, Trivedi MH, Gaynes BN, et al. STAR&z.ast;D: revising conventional wisdom. CNS Drugs. 2009;23(8):627-47.
20. Wisniewski SR, Fava M, Trivedi MH, Thase ME, Warden D, Niederehe G, et al. Acceptability of second-step treatments to depressed outpatients: a STAR&z.ast;D report. Am J Psychiatry. 2007; 164(5):753-60.
21. Warden D, Rush AJ, Wisniewski SR, Lesser IM, Kornstein SG, Balasubramani GK, et al. What predicts attrition in second step medication treatments for depression?: a STAR&z.ast;D Report. Int J Neuropsychopharmacol. 2009;12(4):459-73.
22. Papakostas GI, Petersen TJ, Green C, Iosifescu DV, Yeung AS, Nierenberg AA, et al. A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. Ann Clin Psychiatry Off J Am Acad Clin Psychiatr. 2005;17(3):161-5.
23. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14(4):197-206.
24. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-53.
25. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156-65.
26. Lin CH, Lin SH, Jang FL. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. J Clin Psychopharmacol. 2011;31(5):563-8.
27. Citrome L. Number needed to treat: what it is and what it isn't, and why every clinician should know how to calculate it. J Clin Psychiatry. 2011;72(3):412-3.
28. Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med. 2010;122(4):39-48.
29. Owenby RK, Brown LT, Brown JN. Use of risperidone as augmentation treatment for major depressive disorder. Ann Pharmacother. 2011;45(1):95-100.
30. Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatmentresistant depression: a randomized, open-label, pilot study. J Clin Psychiatry. 2007;68(7):1071-7.
31. Rocca P, Marchiaro L, Rasetti R, Rivoira E, Bogetto F. A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes. Psychiatry Res. 2002;112(2):145-52.
32. Rocca P, Fonzo V, Ravizza L, Rocca G, Scotta M, Zanalda E, et al. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. J Affect Disord. 2002;70(3):313-7.
33. Zanardi R, Smeraldi E. A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2006;16(4):281-7.
34. Bares M, Novak T, Kopecek M, Stopkova P, Kozeny J, Hoschl C. The early improvement of depressive symptoms as a potential predictor of response to antidepressants in depressive patients who failed to respond to previous antidepressant treatments. Analysis of naturalistic data. Eur Psychiatry J Assoc Eur Psychiatr. 2012;27(7):522-7.
35. Henkel V, Seemuller F, Obermeier M, Adli M, Bauer M, Mundt C, et al. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord. 2009;115(3):439-49.
36. Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol. 2006;26(1):56-60.
37. Tadic A, Helmreich I, Mergl R, Hautzinger M, Kohnen R, Henkel V, et al. Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. J Affect Disord. 2010;120(1-3):86-93.
38. Szegedi A, Muller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry. 2003;64(4):413-20.
39. Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry. 1995;152(10): 1500-3.
40. Croxtall JD, Scott LJ. Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder. CNS Drugs. 2010;24(3):245-62.
41. Stewart JW. Treating depression with atypical features. J Clin Psychiatry. 2007;68(Suppl. 3):25-9.
42. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, Markowitz JS, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry. 1988;45(2):129-37.
43. Stewart JW, McGrath PJ, Fava M, Wisniewski SR, Zisook S, Cook I, et al. Do atypical features affect outcome in depressed outpatients treated with citalopram? Int J Neuropsychopharmacol. 2009;3:1-16.
44. Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR&z.ast;D report. Am J Psychiatry. 2008;165(3):342-51.
45. Nelson JC, Thase ME, Bellocchio EE, Rollin LM, Eudicone JM, McQuade RD, et al. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. Int Clin Psychopharmacol. 2012;27(3):125-33.
46. Nelson JC, Mankoski R, Baker RA, Carlson BX, Eudicone JM, Pikalov A, et al. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. J Affect Disord. 2010;120(1-3):133-40.
47. Trivedi MH, Thase ME, Fava M, Nelson CJ, Yang H, Qi Y, et al. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J Clin Psychiatry. 2008;69(12):1928-36.
48. Thase ME, Demyttenaere K, Earley WR, Gustafsson U, Udd M, Eriksson H. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety. 2012;29(7):574-86.
49. Bauer M, El-Khalili N, Datto C, Szamosi J, Eriksson H. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord. 2010;127(1-3):19-30.
50. Berman RM, Thase ME, Trivedi MH, Hazel JA, Marler SV, McQuade RD, et al. Long-term safety and tolerability of openlabel aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatr Dis Treat. 2011;7: 303-12.
51. Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety. 2010;27(10):964-76.
52. Corya SA, Perlis RH, Keck PE Jr, Lin DY, Case MG, Williamson DJ, et al. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry. 2006;67(5): 798-806.
53. Jing Y, Kalsekar I, Curkendall SM, Carls GS, Bagalman E, Forbes RA, et al. Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression. Clin Ther. 2011;33(9):1246-57.
54. Shen H, He MM, Liu H, Wrighton SA, Wang L, Guo B, et al. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos Biol Fate Chem. 2007;35(8):1292-300.
55. Chong SA, Tan CH, Khoo YM, Lee HS, Wong KE, Ngui F, et al. Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia. Ther Drug Monit. 1997;19(2): 219-23.
56. Chen SJ, Hsiao YL, Shen TW, Chen ST. The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial. J Clin Psychopharmacol. 2012;32(1):56-60.
57. Pae CU, Patkar AA, Jun TY, Lee C, Masand PS, Paik IH. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depress Anxiety. 2007;24(7):522-6.
58. Yoshimura RKT, Hori H, Ikenouchi-Sugita A, Katsuki A, Umene-Nakano W, Iwata N, Nakamura J. Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. In Press.
59. Fredman SJ, Fava M, Kienke AS, White CN, Nierenberg AA, Rosenbaum JF. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry. 2000; 61(6):403-8.
60. Kemp DE, Calabrese JR, Eudicone JM, Ganocy S, Tran QV, McQuade RD, et al. Predictive value of early improvement in bipolar depression trials: a post-hoc pooled analysis of two 8-week aripiprazole studies. Psychopharmacol Bull. 2010;43(2):5-27.